Christopher Vaughan
Family · Abilene, TXNPI 1548441967
Payments from drug & device makers
What this record shows
This record is dominated by education: $1,200 of the $1,813 with a category attached, or 66.2%. Pylant Medical accounts for 67.9% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2022 at $1,251 and has fallen 85.8% since, to $177 in 2025.
Across 24 payments — averaging $75.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pylant Medical$1K
- Johnson & Johnson$142
- Smith+Nephew$131
- Bioventus LLC$78
- Baudax Bio Inc.$74
- Vertex$49
- plus $109 from 5 others
What the payments were for
- Food & beverage$61334%
- Education$1,20066%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pylant Medical | 2 | $1,230 |
| Johnson & Johnson(2 entities) | 7 | $142 |
| Smith+Nephew | 1 | $131 |
| Bioventus LLC | 2 | $78 |
| Baudax Bio Inc. | 4 | $74 |
| Vertex | 2 | $49 |
| Ferring Pharmaceuticals Inc. | 2 | $36 |
| Innovation Technologies Inc | 1 | $25 |
| Molnlycke Health Care US, LLC | 1 | $18 |
| Integra Lifesciences Corporation | 1 | $16 |
| Pacira Pharmaceuticals Incorporated | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,813 in reported general payments places this provider in the 75th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Meloxicam | 356 | $1,253 |
| Methocarbamol | 74 | $841 |
| Methylprednisolone | 80 | $481 |
| Tramadol Hcl | 78 | $431 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 21 | $293 |
| Ibuprofen | 15 | $182 |
| Celecoxib | 11 | $136 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $54 |
Paid to pharmacies, not to this prescriber.
Other family in Abilene
- David WeirDallas$959K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
- Angela AchaPflugerville$174K
- Susan BowlinIrving$164K
- Stephanie RodriguezCorpus Christi$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.